Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Acute Lymphoblastic Leukemia
100%
Risk Stratification
100%
In Vitro Sensitivity
100%
Treatment Outcome
100%
Risk Treatment
100%
In Vitro Drug Sensitivity Test
100%
Minimal Residual Disease
75%
In Vivo Applications
50%
Treatment Response
50%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
50%
Spearman
50%
In Vivo Response
50%
B-precursor
50%
Leukemia
25%
L-asparaginase
25%
Event-free Survival
25%
Treatment Intensity
25%
Low Risk
25%
Treatment Stratification
25%
Outcome Prediction
25%
Precursor Cells
25%
Patient Cells
25%
Childhood Acute Lymphoblastic Leukemia
25%
Prednisolone
25%
Precursor B-cell Acute Lymphoblastic Leukemia
25%
Strong Predictor
25%
Incremental Risk
25%
Non-modifiable Risk Factors
25%
Risk Parameters
25%
Predictive Power
25%
Conventional Parameters
25%
Resistant Profile
25%
Reduced Intensity
25%
Power over
25%
Sensitivity Method
25%
In Vivo Assessment
25%
Intensified Therapy
25%
Historical Control
25%
In Vitro Drug Testing
25%
Inpatient Treatment
25%
Medicine and Dentistry
In Vitro
100%
Acute Lymphoblastic Leukemia
100%
Risk Stratification
100%
Drug Sensitivity
100%
Treatment Outcome
100%
Minimal Residual Disease
30%
Precursor
30%
Treatment Response
20%
Leukemia
10%
Event Free Survival
10%
Drug Screening
10%
Vincristine
10%
Asparaginase
10%
Prednisolone
10%
Median Follow Up
10%
Biochemistry, Genetics and Molecular Biology
Precursor
100%
Drug Sensitivity
100%
T Cell
66%
Asparaginase
33%
Drug Screening
33%
Event Free Survival
33%
Prednisolone
33%
Immunology and Microbiology
Drug Sensitivity
100%
In Vitro
100%
Precursor
30%
T Cell
20%
Drug Screening
10%
Event Free Survival
10%
Prednisolone
10%